Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empirical vs Pre-emptive Caspofungin in AML/MDS
NCT01288378Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2012
- Primary completion
- Apr 2019
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of caspofungin in invasive fungal disease (IFD), sponsored by European Organisation for Research and Treatment of Cancer. Started Mar 2012; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive fungal disease (IFD)
Beyond the preview
Go deeper on NCT01288378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01288378.